The US FDA is developing a scientifically rigorous answer to the growing demand from politicians for the agency to conduct unannounced surveillance inspections abroad like it did domestically before the pandemic.
The FDA is relying on a statistical model to conduct a controlled case study of announced versus unannounced inspections, and...